Results 51 to 60 of about 7,168 (203)

In Silico Study of Ceftaroline’s Molecular Properties

open access: yesMedisur, 2011
Background: Ceftaroline is the latest developed cephalosporin. Its molecular modeling can help deepening the structural bases underpinning its pharmacological characteristics.
Elso Manuel Cruz Cruz   +1 more
doaj   +2 more sources

Ceftaroline resistance in Staphylococcus pseudintermedius gene mecA carriers

open access: yesPesquisa Veterinária Brasileira
: Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) being a constant concern, ceftaroline fosamil has been recently approved as a new cephalosporin, active against MRSA, for use in humans; only rare cases of resistance have been ...
Carolina B. Scherer   +4 more
doaj   +1 more source

Ceftaroline-related acute eosinophilic pneumonia

open access: yesLung India, 2021
Ceftaroline fosamil is a novel 5th generation broad-spectrum oxyimino-cephalosporin with activity against Staphylococcus aureus, including methicillin-resistant S.
Zaw Min   +4 more
doaj   +1 more source

Community-acquired pneumonia in children: cell-free plasma sequencing for diagnosis and management. [PDF]

open access: yes, 2019
Community-acquired pneumonia (CAP) is a common cause of pediatric hospital admission. Empiric antibiotic therapy for hospitalized children with serious CAP now targets the most likely pathogen(s), including those that may demonstrate significant ...
Bradley, John S   +8 more
core  

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae [PDF]

open access: yes, 2018
Introduction: Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam.
Doumith, Michel   +5 more
core   +1 more source

Extensive Bilateral Pulmonary Artery Mycotic Pseudoaneurysms Complicating Right‐Sided Infective Endocarditis: A Case Report

open access: yesCase Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Introduction Mycotic aneurysms (MA) are rare but severe complications of infective endocarditis (IE), arising from septic emboli, bacteremia, or direct vascular invasion. Pulmonary artery involvement is particularly uncommon and presents a diagnostic and therapeutic challenge.
Sebastián Hoyos Gutiérrez   +4 more
wiley   +1 more source

Development and validation of an LC-MS/MS method to quantify ceftaroline in microdialysate samples from plasma and brain: Application to a preclinical pharmacokinetic investigation

open access: yesHeliyon, 2023
A bioanalytical LC–MS/MS method was developed and validated to determine ceftaroline in microdialysate samples from plasma and brain. Ceftaroline was separated using a C18 column and a mobile phase consisting of water and acetonitrile, both with 5 mM of ...
Victória Etges Helfer   +8 more
doaj   +1 more source

Uncommon Complications of Osteomyelitis: Deep Vein Thrombosis and Pulmonary Septic Emboli in Two Healthy Pediatric Patients: A Case Report and Literature Review

open access: yesCase Reports in Pediatrics, Volume 2026, Issue 1, 2026.
Acute osteomyelitis in children is typically a localized hematogenous infection; however, its presentation with deep vein thrombosis (DVT) and septic pulmonary emboli (SPE) is exceptionally rare. Fewer than fifteen similar cases have been reported in the literature.
Hala O. Abdallah   +5 more
wiley   +1 more source

Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults

open access: yesJournal of Global Antimicrobial Resistance, 2022
: Objectives: Vancomycin remains a first-line treatment for methicillin-resistant Staphylococcus aureus (MRSA)-mediated acute pulmonary exacerbations (APEs) in adult cystic fibrosis (CF) patients; however, optimal alternatives remain poorly defined. The
Marc D. Esquivel   +4 more
doaj   +1 more source

Antibiotic Use in Livestock: A Driver of Resistance in Africa and the Path to Safer Alternatives

open access: yesMicrobiologyOpen, Volume 14, Issue 6, December 2025.
The incorporation of antibiotics into animal feeds is one of the drivers of antibiotic resistance, a global One Health challenge. To reduce the burden of antibiotic resistance, the use of alternative growth promoters and drugs must be promoted, as well as sensitization and implementation of regulations.
Mercy A. Alabi   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy